cross-posted from: lemmy.zip/post/51540513
Innovent Biologics is teaming up with Japan’s Takeda Pharmaceutical to work on cancer therapies, a deal that could net the Chinese drugmaker up to $11.4 billion.
By 2040, drugs originating in China could account for 35% of approvals by the U.S. Food and Drug Administration, up from only 5% now, according to Morgan Stanley Research.